David Amsellem
Stock Analyst at Piper Sandler
(4.82)
# 94
Out of 5,148 analysts
164
Total ratings
66.17%
Success rate
23.97%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $24.16 | +98.68% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $62.34 | +20.31% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $385.70 | +12.00% | 7 | Feb 18, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $234.26 | +27.64% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $188.05 | -5.88% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $15.70 | -23.57% | 8 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $166.38 | +34.03% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $8.22 | +118.98% | 1 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $30 → $40 | $33.77 | +18.45% | 11 | Dec 22, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $190.46 | +14.98% | 15 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.27 | +175.23% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.21 | +90.02% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $6.02 | +32.89% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $13.77 | -5.59% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $132.38 | +35.22% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $30.25 | +48.76% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $55.09 | +17.99% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $21.01 | +18.99% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $35.97 | +236.39% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.19 | +150.35% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $41.60 | -11.06% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $75.22 | -9.60% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.95 | -49.58% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $21.28 | +97.37% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.57 | +488.24% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $28.90 | +45.33% | 3 | Oct 16, 2023 |
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $24.16
Upside: +98.68%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $62.34
Upside: +20.31%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $385.70
Upside: +12.00%
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $234.26
Upside: +27.64%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $188.05
Upside: -5.88%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $15.70
Upside: -23.57%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $166.38
Upside: +34.03%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $8.22
Upside: +118.98%
Teva Pharmaceutical Industries
Dec 22, 2025
Maintains: Overweight
Price Target: $30 → $40
Current: $33.77
Upside: +18.45%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $190.46
Upside: +14.98%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.27
Upside: +175.23%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.21
Upside: +90.02%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.02
Upside: +32.89%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $13.77
Upside: -5.59%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $132.38
Upside: +35.22%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $30.25
Upside: +48.76%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $55.09
Upside: +17.99%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $21.01
Upside: +18.99%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $35.97
Upside: +236.39%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.19
Upside: +150.35%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $41.60
Upside: -11.06%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $75.22
Upside: -9.60%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.95
Upside: -49.58%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $21.28
Upside: +97.37%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.57
Upside: +488.24%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $28.90
Upside: +45.33%